Insulin, Neurogenetics and Memory in Alzheimer's Disease

• Status: Completed
• Trial end date: 2003-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Rosiglitazone

Criteria

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.